Dr. Patrice Hugo recently co-authored a white paper with IQVIA about restarting clinical trials in Asia Pacific following the COVID-19 pandemic. The recent restrictions imposed by many countries in response to the COVID-19 outbreak has impacted ongoing clinical research, and restarting clinical trials is a critically important activity. This paper investigates how research sites are utilizing a variety of measures, including diagnostic tests, in an attempt to minimize risk of external transmission of the infection to staff and patients at the site.

Complete the form below to access this white paper